Mounjaro®
Starting from £179.99/mo
Start journey Learn moreThere is no 60mg tirzepatide weight loss pen. The figure circulates online, but no such dose exists in the UK or anywhere else. Tirzepatide is licensed in six strengths — 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg and 15mg — and each Mounjaro KwikPen holds four of your weekly doses at a single strength. Understanding what the pen actually contains matters, because confusion about dosing can lead people toward unverified sources selling products that do not exist. These are prescription-only medicines that require a clinical assessment before any prescriber can approve them, a fact that protects you as much as it regulates the market.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
This is the single biggest misconception built around this search query, and it is worth tackling head-on. No medicines regulator (not the MHRA, not the EMA, not the FDA) has approved a 60mg tirzepatide pen for any indication. The licensed UK product, Mounjaro, comes in six fixed strengths. The highest is 15mg once weekly. The 60mg figure may arise from people misreading the pen's total content (a single KwikPen holds four doses, so a 15mg pen contains 60mg of tirzepatide in total across those four injections), but that total volume is never administered at once, and it is not a licensed dose.
This distinction is not a technicality. Sellers who advertise a "60mg weight loss pen" are either describing their product incorrectly or selling something that falls outside the licensed supply chain. Both situations carry real risk. The MHRA has seized approximately 20 million doses (around £45 million street value) of illegally traded weight-loss medicines, including counterfeit tirzepatide pens raided from an illicit manufacturing site in Northampton in October 2025. If you encounter any seller offering a 60mg tirzepatide pen, that is a clear prompt to walk away and report the listing at yellowcard.mhra.gov.uk.
The Mounjaro KwikPen is a pre-filled, disposable device with four weekly doses pre-loaded at a single strength. A 2.5mg pen delivers 2.5mg per injection across four weeks; a 15mg pen delivers 15mg per injection. Each pen has its own colour-coded label precisely to prevent mix-ups. You use the pen once a week, on the same day each week if possible, and replace it with a fresh one the following month.
Treatment starts at 2.5mg. That first dose exists to let your digestive system adjust, nausea and mild GI discomfort are most likely in the early weeks, and starting low reduces how severe those effects tend to be. Your prescriber typically reviews your response after four weeks and decides whether to move you up to 5mg, and so on through the schedule. The titration is clinical, not automatic. For a full walk-through of how the pen is used in practice, the step-by-step injection guide covers technique, rotation sites and storage in detail.
Storage is straightforward day-to-day: keep the pen refrigerated between 2°C and 8°C. There is a limited window during which it can be kept at room temperature, but the exact duration is specified in the Patient Information Leaflet rather than here, the leaflet is the right document for that, and it comes with every pen. A pack of alcohol swabs is worth having nearby; cleaning the injection site before each use is standard practice.
The licensed criteria for tirzepatide in the UK (set out in the SmPC and summarised by the NHS medicines page for tirzepatide) cover adults with a BMI of 30 or above, or those with a BMI from 27 upward if at least one weight-related condition is present (such as high blood pressure, type 2 diabetes, high cholesterol or obstructive sleep apnoea). Lower thresholds apply for some ethnic backgrounds under UK clinical guidance. A BMI figure alone does not guarantee approval; the prescriber considers the whole clinical picture, including current medicines, past history and whether anything in your background contraindicates treatment.
Tirzepatide is not licensed for anyone under 18, and it is not recommended during pregnancy, breastfeeding or while actively trying to conceive. If you take an oral contraceptive pill, your prescriber will explain the guidance around adding a non-oral method for the first four weeks of treatment and for four weeks after each dose increase, because absorption of the pill can be affected.
At nume, a GPhC-registered Independent Prescriber reads your consultation (a real clinician, not a decision algorithm) and responds the same day. If you order by midday on a working day and your prescription is approved, the pen is dispatched that afternoon and arrives with DPD the next working day in plain, unbranded packaging. If you would like to understand more about how the weight loss pen tirzepatide works, including its mechanism and what to expect from treatment, that page covers the detail clearly. For an overview of what private tirzepatide treatment costs, including what a legitimate price should cover, that page sets out the full picture honestly. If you are ready to see whether you qualify, the starting point is a free consultation with our prescribers.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.